drugset / Trial / NCT00434967

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo

NCT00434967

Phase 3 Completed 2207 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in hypertensive adults.

Timeline

Start
2007-01
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Candesartan cilexetil Unknown 32 mg Oral
Subject Hydrochlorothiazide Unknown 25 mg Oral

Indications